Skip to main content Accessibility help
×
Home

Infantile-onset pompe disease: a tale of two cases

  • Drishti Tolani (a1), Neha Bansal (a2) and Swati Sehgal (a1)

Abstract

Pompe disease is a type-II glycogen storage disease, and clinical manifestations include hypertrophic cardiomyopathy and generalised muscular hypotonia. Enzyme replacement therapy has proven to be effective in reversing the ventricular hypertrophy. The outcomes are variable depending on time to diagnosis and severity of the cardiac disease. We describe two contrasting cases of patients with infantile-onset Pompe disease. The first child was diagnosed late and had severe cardiac hypertrophy with respiratory decompensation and ventilator dependence and eventual death. The second case was diagnosed at birth with early initiation of therapy resulting in a good outcome. Our cases highlight the importance of early initiation of enzyme replacement therapy to improve clinical outcomes.

Copyright

Corresponding author

Author for correspondence: Neha Bansal, Division of Pediatric Cardiology, Children’s Hospital at Montefiore, 3415 Bainbridge Ave- R1, Bronx, NY10467, USA. Tel: 718-741-2313; Fax: (718) 920-4351; E-mail: nbansal@montefiore.org

References

Hide All
1.Chen, M, Zhang, L, Quan, S.Enzyme replacement therapy for infantile-onset Pompe disease. Cochrane Database Syst Rev 2017; 11: Cd011539.
2.Kishnani, PS, Hwu, WL, Mandel, H, Nicolino, M, Yong, F, Corzo, D.A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006; 148: 671676.10.1016/j.jpeds.2005.11.033
3.Bali, DS, Goldstein, JL, Banugaria, S, et al.Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet 2012; 160c: 4049.10.1002/ajmg.c.31319
4.Nicolino, M, Byrne, B, Wraith, JE, et al.Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 2009; 11: 210219.10.1097/GIM.0b013e31819d0996
5.Levine, JC, Kishnani, PS, Chen, YT, Herlong, JR, Li, JS.Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. Pediatr Cardiol 2008; 29: 10331042.10.1007/s00246-008-9267-3
6.Raben, N, Jatkar, T, Lee, A, et al.Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol Ther 2002; 6: 601608.10.1016/S1525-0016(02)90716-1
7.van Gelder, CM, Poelman, E, Plug, I, et al.Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study. J Inherit Metab Dis 2016; 39: 383390.10.1007/s10545-015-9912-y
8.Hordeaux, J, Dubreil, L, Robveille, C, et al.Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease. Acta Neuropathol Commun 2017; 5: 66.10.1186/s40478-017-0464-2
9.Chen, LR, Chen, CA, Chiu, SN, et al.Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease. J Pediatr 2009; 155: 2715.e2.10.1016/j.jpeds.2009.03.015

Keywords

Related content

Powered by UNSILO

Infantile-onset pompe disease: a tale of two cases

  • Drishti Tolani (a1), Neha Bansal (a2) and Swati Sehgal (a1)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.